# A Pharmacokinetics/Dynamics Ib Study of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy

> **NCT02522234** · PHASE1,PHASE2 · COMPLETED · sponsor: **EVIVE Biotechnology** · enrollment: 15 (actual)

## Conditions studied

- Neutropenia

## Interventions

- **BIOLOGICAL:** F-627 240 μg/kg
- **BIOLOGICAL:** F-627 320 μg/kg

## Key facts

- **NCT ID:** NCT02522234
- **Lead sponsor:** EVIVE Biotechnology
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-02-25
- **Primary completion:** 2015-08-19
- **Final completion:** 2015-08-19
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2019-11-21

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02522234

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02522234, "A Pharmacokinetics/Dynamics Ib Study of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02522234. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*